Last updated: February 13, 2026
What is the market status of the drug NDC 43485-0102?
NDC 43485-0102 corresponds to Epidiolex (cannabidiol) oral solution. Approved by the U.S. Food and Drug Administration (FDA) in 2018, it is indicated for treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged 2 years and older.
Epidiolex holds a unique position as the first FDA-approved plant-derived cannabidiol medication. It has secured substantial market share within the niche of rare pediatric epilepsy, supported by regulatory exclusivity and marketing authorization.
What are the current market dynamics?
Market size and growth
From its launch through 2022, Epidiolex has experienced consistent growth. The reported global retail sales reached approximately $600 million in 2022. The U.S. accounts for most sales, driven by:
- High prevalence of Lennox-Gastaut syndrome and Dravet syndrome.
- Limited alternative treatments approved for these indications.
- Prescriber familiarity with Epidiolex fueled by its FDA approval.
The compound's market growth rate has been approximately 20% annually from 2020 to 2022. Future growth depends on:
- Expansion into new indications.
- Off-label use trends.
- Increasing acceptance of cannabis-derived medications.
Market challenges
Competition includes off-label use of compounded cannabidiol products and other anti-epileptic drugs. The entry of biosimilars or generics remains unlikely in the near term due to patent protections and regulatory exclusivity.
Regulatory landscape
Epidiolex has held orphan drug designation, granting seven years of market exclusivity in the U.S. starting 2018. Similar protections exist in Europe and other markets. Patent expiry is not projected before 2030, reinforcing market dominance.
What are price trends and projections?
Current pricing
The average wholesale price (AWP) for Epidiolex (100 mg/mL) in the U.S. is approximately $1.50 per mL. Typical treatment involves 10-20 mL daily, resulting in:
- Monthly costs: $45 to $90.
- Annual costs: $540 to $1,080.
Insurance coverage varies, but Epidiolex is generally reimbursed, facilitating market penetration.
Price projections (next 3-5 years)
- Stability expected. The current price structure is maintained due to high regulatory barriers against generics and limited competition.
- Potential for pricing pressure. If similar formulations or biosimilars enter the market post-exclusivity, prices could decline by 10-20% over 3-5 years.
- Additional indications or formulations. Expansion into other neurological conditions could command premium pricing, sustaining higher revenues.
What are the key factors influencing market and pricing?
- Regulatory exclusivity. Protects Epidiolex from generic competition until at least 2025-2028.
- Patent life. Patents protect formulation and method of use. Patent expiry projected before 2030.
- Off-label use and physician acceptance. Growing familiarity supports ongoing demand.
- Market entry barriers. Cannabinoid-based drugs face regulatory restrictions, which limit competition.
Summary
Epidiolex (NDC 43485-0102) commands a stable and growing market within rare pediatric epilepsy. Sales are projected to remain stable at current price levels over the next 3-5 years, with potential reductions if Biosimilar or generic competition materializes post-patent exclusivity and regulatory protections.
Key Takeaways
- Epidiolex generated $600 million in global sales in 2022.
- Price remains around $1.50 per mL, with annual costs between $540 and $1,080 per patient.
- Market growth driven by regulatory exclusivity and limited competition.
- Price declines likely only after patent and exclusivity periods end around 2025-2028.
- Expansion into other indications could augment revenues but require additional approvals.
FAQs
1. When do patent protections for Epidiolex expire?
Patents related to Epidiolex are projected to expire between 2025 and 2028, barring extensions or new patent filings.
2. Are there approved biosimilars or generics for Epidiolex?
No biosimilars or generics are approved or launched yet, mainly due to current patent protections and regulatory exclusivity.
3. What are the main competitors to Epidiolex?
No direct FDA-approved cannabidiol alternatives exist; off-label compounded products comprise a competitive challenge, but formal alternatives are limited.
4. How might regulatory changes impact pricing?
Relaxation of cannabidiol drug regulations or approval of similar products could induce price reductions and market share redistribution.
5. What is the outlook for new indications?
Further approvals for other epileptic or neurological disorders could sustain or increase demand, supporting higher pricing strategies.
Sources:
[1] FDA. Epidiolex (cannabidiol) Prescribing Information. 2018.
[2] IQVIA. National Prescription Data. 2022.
[3] EvaluatePharma. Worldwide Sales Data. 2022.
[4] U.S. Patent & Trademark Office. Patent expiry estimates.
[5] Company Financial Reports. 2022.
